Baxter International Inc.’s Stock Price Drops to $33.61, Experiences 3.72% Decline

Baxter International Inc. (BAX)

33.61 USD -1.30 (-3.72%) Volume: 7.05M

Baxter International Inc.’s stock price stands at 33.61 USD, marking a decrease of -3.72% this trading session. With a trading volume of 7.05M, BAX’s stock performance shows a year-to-date (YTD) percentage change of -13.06%, indicating a challenging year for the healthcare company in the stock market.

Latest developments on Baxter International Inc.

Today, Baxter International stock experienced a significant increase following reports of Carlyle’s interest in potentially acquiring its kidney care unit, Vantive. This news comes after Baxter’s successful recovery from the Life2000 Ventilation Systems recall. Additionally, Van ECK Associates Corp recently purchased a new position in Baxter International, while Sumitomo Mitsui Trust Holdings Inc. sold some of its shares. Carlyle’s potential $4 billion acquisition of Vantive has caught the attention of investors, leading to a surge in Baxter’s stock price.

Baxter International Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma have published a bullish report on Baxter International, highlighting the company’s strong performance in the first quarter of 2024. The report, titled “Baxter International: Driving Revenue with New Innovations and Competitive Conversions! – Major Drivers,” notes that Baxter exceeded its guidance with 2% growth on a reported basis and 3% at constant currency rates. This growth was driven by strong demand and favorable pricing for a wide range of Baxter’s products, showcasing the benefits of the company’s recent strategic transformation.

The research report by Baptista Research emphasizes Baxter International‘s improved global visibility, enhanced accountability, and functional verticalization as key contributors to its success. The analysts are optimistic about the company’s future prospects based on its strong performance in the first quarter of 2024. Investors can access the full report on Baxter International on Smartkarma’s independent investment research network to gain valuable insights into the company’s growth trajectory and potential investment opportunities.

A look at Baxter International Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, Baxter International has a strong outlook for its dividend and value factors, scoring a 5 and 4 respectively. This indicates that the company is performing well in terms of providing returns to its shareholders and being undervalued in the market. However, the growth and resilience scores are lower at 2, suggesting that there may be challenges in terms of expanding its business and withstanding economic downturns. The momentum score of 3 indicates a moderate level of market interest and activity in the company.

Baxter International Inc. is a company that focuses on developing and manufacturing products related to various medical conditions such as hemophilia, kidney disease, and infectious diseases. Its products are widely used in healthcare settings such as hospitals, dialysis centers, and doctors’ offices. With a strong dividend and value outlook, investors may find Baxter International to be a promising investment option despite lower scores in growth and resilience factors.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma